FREEHOLD, N.J., June 13, 2019 /PRNewswire/ -- Avalon
GloboCare Corp. (NASDAQ: AVCO), a leading global developer of
cell-based technologies and therapeutics, announced today the
Company's President and Chief Executive Officer, David Jin. M.D., Ph.D., will participate at the
Second International Aesthetic Industry Conference in Chengdu, China, the largest scale of its kind
across all of Asia.
Dr. Jin will lead the "Application of Stem Cell Exosomes"
session, acting as both chair and speaker of the panel. At this
time, Dr. Jin will also unveil the launch of Avalon's new exosome
product commercialization plan. The company will be providing a
series of skincare and wound-healing products with Avalon's
Clinical-grade Tissue-specific EXosomes as
additives (ACTEX).
Additionally, Yu Zhou, the Co-CEO
of Avalon's subsidiary GenExosome Technologies, will provide the
conference keynote address. GenExosome Technologies
developed the proprietary exosome isolation systems in order to
promote implementation of exosome biotechnology in "liquid
biopsies" and provide innovative exosome products for clinical
diagnosis and treatment. Yu Zhou's
keynote presentation is titled "Application of Exosome Technology
in Aesthetic Industry: Isolation, Quality Control, and Exosomic
Analysis."
"Avalon GloboCare is dedicated to assembling and integrating the
premier scientific, clinical, and regulatory resources from around
the world, in order to accelerate innovative and transformative
cellular and exosome-based technologies, as well as their clinical
applications," stated Dr. Jin. "We are honored to lead a panel with
international experts to discuss this evolving ecosystem, as well
as showcasing our exosome product commercialization plan."
For more information on the conference, please see below:
Session Information:
Date: June 15, 2019
Time: 3:30 pm – 6:30 pm
Venue: Century City New International Convention and Exhibition
Center, Chengdu, China
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a leading CellTech
bio-developer dedicated to advancing and empowering innovative,
transformative exosome technologies and cellular therapeutics.
Avalon also provides strategic advisory and outsourcing services to
facilitate and enhance its clients' growth, development, as well as
competitiveness in both the domestic and global healthcare markets.
Through its subsidiaries, namely GenExosome Technologies Inc. and
Avactis Biosciences Inc., Avalon is establishing a leading role in
the fields of exosome-based diagnostics (''liquid biopsy''),
cellular immunotherapy (including CAR-T/CAR-NK), and regenerative
medicine.
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements." Forward-looking
statements provide current expectations of future events based on
certain assumptions and include any statement that does not
directly relate to any historical or current fact. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors as disclosed in
our filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to
these factors, actual future performance, outcomes, and results may
differ materially because of more general factors including
(without limitation) general industry and market conditions and
growth rates, economic conditions, and governmental and public
policy changes. The forward-looking statements included in this
press release represent the Company's views as of the date of this
press release and these views could change. However, while the
Company may elect to update these forward-looking statements at
some point in the future, the Company specifically disclaims any
obligation to do so. These forward-looking statements should not be
relied upon as representing the Company's views as of any date
subsequent to the date of the press release.
View original
content:http://www.prnewswire.com/news-releases/avalon-globocare-president-and-ceo-david-jin-md-phd-to-chair-the-research-and-application-of-stem-cell-exosomes-session-at-this-years-second-international-aesthetic-industry-conference-300866917.html
SOURCE Avalon GloboCare Corp.